CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Echo Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Echo Therapeutics Inc
1809 HUDSON PARK
Phone: (732) 549-0919p:732 549-0919 EDGEWATER, NJ  07020  United States Ticker: XS5BXS5B

On April 13, 2015, the management of Echo Therapeutics, Inc. determined that the Company’s financial statements issued for the quarterly period ended September 30, 2014 could no longer be relied upon as a result of the write-off of deferred financing costs in the third quarter of 2014 that should have been written-off in the fourth quarter of 2014. In its quarterly report for the period ended September 30, 2014, the Company stated that due to its inability to cause Platinum Montaur (“PM”) to advance funds pursuant to the 2012 Credit Facility (“CF”), since draws were made at PM’s discretion in accordance with the Loan Agreement, the Company elected to terminate the CF it had with PM. Accordingly, on October 28, 2014, the Company notified PM that it was irrevocably canceling and terminating the CF effective as of October 30, 2014. In the third quarter of 2014 the Company fully amortized the remaining $2,823,325 of deferred financing costs related to the CF that the Company had with PM stating that since the Company was not able to borrow against the CF, it was terminating the CF shortly, and therefore expensing all the related deferred financing costs.
This company is no longer actively traded on any major stock exchange.

Business Summary
Echo Therapeutics, Inc. is a medical device company. The Company is engaged in developing a non-invasive, wireless continuous glucose monitoring (CGM) system with use in the wearable-health consumer market, diabetes outpatient market and in the hospital setting. The Company operates through the development of transdermal skin permeation and diagnostic medical devices segment. The Company has also developed its needle-free skin preparation device as a platform technology that allows for enhanced skin permeation enabling extraction of analytes, such as glucose, enhanced delivery of topical pharmaceuticals and other applications. The CGM System includes a skin preparation device, transdermal glucose sensor, battery and wireless transmitter. The Company has conducted several human feasibility clinical studies with its CGM System in healthy subjects, diabetics and critically ill patients, as well as a clinical study at several hospitals in the United States.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/201612/31/2015YesYes---

Industries
SIC Code Description
3845 Electromedical and electrotherapeutic apparatus

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chief Executive Officer, Chief Financial Officer, Secretary, Director Alan W.Schoenbart 58 3/21/2017 12/29/2014

Business Names
Business Name
ECTE
Sontra Medical, Inc.
XS5B

General Information
Number of Employees: 17 (As of 3/1/2016)
Outstanding Shares: 12,004,308 (As of 12/30/2016)
Shareholders: 129
Stock Exchange: OTC
Federal Tax Id: 411649949
Fax Number: (302) 636-5454
Email Address: info@sontra.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023